NEPH

Business Context and Reporting Period

Company: Nephros, Inc. (NEPH)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Nephros develops and markets high-performance water filtration solutions for medical (infection control, dialysis) and commercial markets. The company operates as a single reporting segment and is classified as a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 7% ($335,000) driven by programmatic product sales growth, partially offset by a decline in non-recurring emergency response business compared to Q1 2025.
• Margin Compression: Gross margin decreased 8 percentage points (from 65% to 57%). Management attributed this to higher product costs due to the weakening US Dollar against the Euro, tariffs implemented in May 2025, and a revenue mix shift toward lower-margin commercial products.
• Operating Expenses: Total operating expenses rose 12% ($308,000). Selling, general, and administrative (SG&A) expenses increased 12% due to higher headcount and professional fees. R&D expenses increased 17% due to salary increases from added headcount.
• Cash Flow Deterioration: The company shifted from generating $0.32 million in operating cash flow in Q1 2025 to using $1.67 million in Q1 2026. This was primarily caused by a $1.1 million increase in accounts receivable and a $0.8 million decrease in accrued expenses.
• Liquidity: Cash balances declined from $5.40 million at year-end 2025 to $4.02 million at March 31, 2026.

Outlook, Risks, and Contingencies

• Liquidity Position: Management believes current cash balances are sufficient to fund operations for at least the next 12 months. However, the company maintains an accumulated deficit of $143 million and may incur future losses if revenue targets are not met.
• Internal Control Material Weakness: The company disclosed a material weakness in internal controls over financial reporting related to revenue recognition for contracts with multiple performance obligations (products and services). While no material misstatement occurred, remediation efforts are ongoing.
• Supply Chain and Tariffs: The company faces risks related to supply chain disruptions and increased costs from U.S. tariffs. A subsequent event noted a Supreme Court ruling invalidating certain IEEPA-based tariffs; the company applied for a refund of $646,698 in April 2026, though receipt is uncertain.
• Customer Concentration: Three customers accounted for 38% of revenue in Q1 2026. Four customers accounted for 47% of accounts receivable.
• License Agreement: The company has a minimum purchase commitment with its sole supplier of filter material (Medica) through 2030. Failure to meet these commitments could result in termination of the agreement.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $1.67 million operating cash outflow and the timeline to return to positive cash flow.
• Margin Recovery: Assess the impact of currency fluctuations and tariffs on future gross margins and the ability to pass costs to customers.
• Internal Controls: Monitor the progress of remediation for the material weakness in revenue recognition controls.
• Receivables Quality: Review the aging of the $3.52 million accounts receivable balance, given the significant increase in the quarter and customer concentration.
• Tariff Refund Status: Track the status of the $646,698 tariff refund application filed in April 2026.